Molecules involved in T–B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity

Bibliography

• SHARP AH, FREEMAN JG: The B7-CD28 superfamily. Nat. Rev Iminunol (2002) 2:116–126.
   PubMed Web of Science ®Google Scholar
• ••Excellent review.
   Google Scholar
• CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. AMU. Rev Inununol. (2002) 20:29–53.
   PubMed Web of Science ®Google Scholar
• ••Two very comprehensive reviews of thecurrent knowledge on new members of the B7 and CD28 families, their co-stimulatory pathways and regulatory potential also in view of therapeutic Interventions.
   Google Scholar
• KROCZEK RA, GRAF D, BRUGNONI D et al: Defective expression of CD40 ligand on T cells causes X-linked immunodeficiency with hyper IgM (HI GM1) Iminunol Rev (1994) 138:39–59.
   Google Scholar
• •Important review on how the CD40-CD4O-L defects in humans affect the immune reponse.
   Google Scholar
• WEINBERG AD: 0X40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines. Trends Iminunol (2002) 23:102–109.
   PubMed Web of Science ®Google Scholar
• •Elegant and informative review.
   Google Scholar
• MOORE PA, BELVEDERE 0, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 285:260–263.
   Google Scholar
• •First description of BLyS.
   Google Scholar
• YU G: APRIL stimulates B and T cell function by binding BCMA and TACI. Nat. Inununol. (2000) 1:253–256.
   Google Scholar
• NG LG, SUTHERLAND AP, NEWTON R et al.: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Inununol. (2004) 173:807–817.
   Google Scholar
• STOHL W: Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr. Opin. Rheumatol. (2002) 14:522–528.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the role of BAFF and APRIL in autoimmune diseases.
   Google Scholar
• HUTLOFF A, DITTRICH AM, BEIER KC et al:ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 397:263-266. Discovers ICOS as a CD28 homologue on activated human T cells, and shows that ICOS crosslinking in conjunction with a T cell receptor signal upregulates cytokine production, particularly of IL-10 but not of IL–2.
   Google Scholar
• ISHIDA Y, AGATA Y, SHIBAHARA K, HONJO T: Induced expression of PD-1. A novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. (1992) 11:3887–3895.
   Google Scholar
• ••First description of the PD-1 receptor.
   Google Scholar
• CARRENO BM, COLLINS M: BTLA: a new inhibitory receptor with a B7-like ligand. Trends Iminunol (2003) 10:524–527.
   Google Scholar
• •Comprehensive review on BTLA and its ligand.
   Google Scholar
• GREENWALD RJ, LATCHMAN YE, SHARPE AH: Negative co-receptors on lymphocytes. Curr. Opin. Iminunol (2002) 14:391–396.
   PubMed Web of Science ®Google Scholar
• OKAZAKI T, IWAI Y, HONJO T: New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Inununol. (2002) 14:779–782.
   PubMed Web of Science ®Google Scholar
• CHEN LP: Co-inhibitory molecules of theB7-CD28 family in the control of T cell immunity. Nat. Rev Inonunol. (2004) 4:336–347.
   PubMed Web of Science ®Google Scholar
• LIANG L, SHA WC: The right place at theright time: novel B7 family members regulate effector T cell responses. Curr. Opin. Inununol. (2002) 14:384–390.
   PubMed Web of Science ®Google Scholar
• FRAUWIRTH KA, THOMPSON CB: Activation and inhibition of lymphocytes by costimulation. Clin. Invest. (2002) 109:295–299.
   Google Scholar
• LOKE P, ALLISON JP: Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res.Ther. (2004) 6:208–214.
   PubMed Web of Science ®Google Scholar
• GRIMBACHER B, WARNATZ K, PETER HH: The immunological synapse for B cell memory: the role of ICOS and its ligand for the longevity of humoral immunity. Curl: Opin. Allergy Clin. Inununol. (2003) 3:409–419.
   PubMed Web of Science ®Google Scholar
• FEITO MJ, VASCHETTO R, CRIADO G et al.: Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways. Eur. Inununol. (2003) 33:204–214.
   Google Scholar
• RUDD CE, SCHNEIDER H: Unifying concepts in CD28, ICOS and CTLA4 co- receptor signaling. Nat. Rev Inonunol. (2003) 3:544–556.
   PubMed Web of Science ®Google Scholar
• ••Important and extensive review of currentknowledge on signalling pathways engaged by the three co-receptors of the CD28 receptor family.
   Google Scholar
• COYLE AJ, LEHAR S, LLOYD C et al: The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Iminunio, (2000) 13:95–105.
   PubMed Web of Science ®Google Scholar
• YOSHINAGA SK, WHORISKEY JS, KHARES SD et al: T cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 402:827–832.
   PubMed Web of Science ®Google Scholar
• HARADA Y, OHGAI D, WATANABE R et al: A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS). Exp. Med. (2003) 197:257–262.
   PubMed Web of Science ®Google Scholar
• ARIMURA Y, KATO H, DIANZANI U et al: A co-stimulatory molecule on activated T cells, H4/ICOS, delivers specific signals in T(h) cells and regulates their responses. Int. Iminunol (2002) 14:555–566.
   PubMed Web of Science ®Google Scholar
• ••This important study provides firstinsights into intracellular signalling events that differ in ICOS and CD28 costimulation of murine CD4' T cells. Increased IL-4, IL-10 and IFN-y production in ICOS costimulated T cells is associated with strong activation of the P13-K-DK1-Akt/PKB pathway. Interestingly, the natural skewing towards TH2 cytokine responses in Balb/c versus TH1-dominated cytokine responses in C57B1/6 mice is associated with a higher expression of ICOS on Balb/c versus C57131/6 CD4+.
   Google Scholar
• RILEY JL, MAO M, KOBAYASHI S et al:Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Nati Acad. Li. USA (2002) 99:11790–11795.
   PubMed Web of Science ®Google Scholar
• MCADAM AJ, GREENWALD RJ, LEVIN MA et al:ICOS is critical for CD40-mediated antibody class switching. Nature (2001) 409:102–105.
   PubMed Web of Science ®Google Scholar
• DONG C, JUEDES AE, TEMANN UA et al: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 409:97–101.
   PubMed Web of Science ®Google Scholar
• TAFURI A, SHAHINIAN A, BLADT F et al:ICOS is essential for effective T-helper-cell responses. Nature (2001) 409:105-109. Expert Opin. Biol. Ther. (2005) 5\(Supp1.1)
   Google Scholar
• DONG C, TEMANN UA, FLAVELL RA: Cutting edge: critical role of inducible costimulator in germinal center reactions. I Immunol (2001) 166:3659–3662.
   PubMed Web of Science ®Google Scholar
• WONG SC, OH E, NG CH, LAM KP: Impaired germinal center formation and recall T cell-dependent immune responses in mice lacking the co-stimulatory ligand B7-H2. Blood(2003) 102:1381–1388.
   PubMed Web of Science ®Google Scholar
• MAK TW, SHAHINIAN A, YOSHINAGA SK et al.: Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell dependent B cell responses. Nat. Immunol. (2003) 4:765–772.
   PubMed Web of Science ®Google Scholar
• HUTLOFF A, BUCHNER K, REITER K et al.: Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. (2004) 50:3211–3220.
   PubMed Web of Science ®Google Scholar
• GRIMBACHER B, HUTLOFF A, SCHLESIER M et al: Homozygous loss of ICOS is associated with adult onset common variable immunodeficiency. Nat. Immunol (2003) 4:261–268.
   PubMed Web of Science ®Google Scholar
• ••First description of human ICOSdeficiency: the paper points out the differences between murine and human
   Google Scholar
• SALZER U, MAUL-PAVICIC A, CUNNINGHAM-RUNDLES C et al: ICOS-deficiency in patients with common variable immunodeficiency. Clin. Immunol (2004) 113:234–240.
   PubMed Web of Science ®Google Scholar
• •Largest cohort of CVID patients screened for ICOS deficiency so far. Of the tested CVID patients, 4.7% suffered from ICOS deficiency.
   Google Scholar
• PEACH RJ, BAJORATH J,BRADY W et al.: Complementarity determining regionl (CDR1) and CDR3 analogous regions in CTLA-4 and CD28 determine the binding of B7-1.1 Exp. Med. (1994) 180:2049–2058.
   Google Scholar
• LINSLEY PS, GREENE JL, BRADY W et al: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1:793-801 (Erratum Immunity (1995) 2:203a).
   Google Scholar
• GREENE JL, LEYTZE GM, EMSWILER J et al: Covalent dimerisation of CD28/CTLA-4 and oligomerisation of CD80/CD86 regulates T cell costimulatory interactions. J. Biol. Chem. (1996) 271:26762–26771.
   PubMed Web of Science ®Google Scholar
• VIJAYAKRISHNAN L, SLAVIK JM, ILLES Z et al: An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 20:563–575.
   PubMed Web of Science ®Google Scholar
• PROBST HC, MCCOY K, OKAZAKI T, HONJO T, VAN DEN BM: Resting dendritic cells induce peripheral CDS+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol (2005) 6:280–286.
   PubMed Web of Science ®Google Scholar
• KREMER JM, WESTHOVEN R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA-41g. N. Engl. J. Med. (2003) 349(20):1907–1915.
   PubMed Web of Science ®Google Scholar
• SHINORA T, TANIWAKI M, ISHIDA Y, KAWAICHI M, HONJO T: Structure and chromosomal localisation of the human PD-1 gene (PD C1). Cenomics (1994) 23:704–706.
   Google Scholar
• NISHIMURA H, NOSE M, HIAI H, MINATO N, HONJO T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM-motif carrying immunoreceptor. ImmuniO, (1999) 11:141–151.
   PubMed Web of Science ®Google Scholar
• •First description of PD-1 function.
   Google Scholar
• NISHIMURA H, OKAZAKI T, TANAKA Y et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science (2001) 291:319–322.
   PubMed Web of Science ®Google Scholar
• •Important observations on the role of PD-1 in controlling autoimmune diseases.
   Google Scholar
• TSAO BP: The genetics of human systemic lupus erythematosus. Trends Immunol. (2003) 24(10:595–602.
   PubMedGoogle Scholar
• WATANABE N: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol (2003) 4:630–638.
   Google Scholar
• ••First description of a novel T and B cellattenuator in the CD28-B7 superfamily.
   Google Scholar
• WATERHOUSE P, PENNINGER JM, TIMMS E et al.: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science (1995) 270:985–988.
   PubMed Web of Science ®Google Scholar
• ••Important paper on the biological role ofCTLA-4.
   Google Scholar
• BATTEN M, GROOM J, CACHERO TG et al: BAFF mediates survival of peripheral mature B lymphocytes. I Exp. Med. (2000) 192:1453–1465.
   PubMed Web of Science ®Google Scholar
• •Important observation on the biological role of BAFE
   Google Scholar
• MACKAY F, SCHNEIDER P, RENNERT P, BROWNING J: BAFF and APRIL: a tutorial on B cell survival. Ann. Rev Immunol (2003) 21:231–264.
   PubMed Web of Science ®Google Scholar
• THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 293:2108–2111.
   PubMed Web of Science ®Google Scholar
• •Discovery of the BAFF-R as a critical receptor for BAFF effects on B cells.
   Google Scholar
• HAHNE M, KATAOKA T, SCHRODER M et al: APRIL, a new ligand of the tumor necrosis factor family stimulates tumor cell growth. Exp. Med. (1998) 188:1185–1190.
   PubMed Web of Science ®Google Scholar
• XU S, LAM KP: B cell maturation protein which binds the tumor necrosis factor family members BAFF and APRIL, is indispensable for humoral immune responses. Mol. Cell. Biol. (2001) 21:4067–4074.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, MACKAY F, STEINER Fet al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. I Exp. Med. (1999) 189:1747–1756.
   Google Scholar
• MACKAY F, MACKAY CR: The role ofBAFF in B cell maturation, TR cell activation and autoimmunity. Trends Immunol (2002) 23(3):113–115.
   PubMed Web of Science ®Google Scholar
• SCHIEMANN B, GOMMERMAN JL, VORA K et al: An essential role for BAFF in the normal development of B cells through a BCMA independent pathway. Science (2001) 293:2111–2114.
   PubMed Web of Science ®Google Scholar
• •The authors demonstrate the important role for BAFF in normal B cell development.
   Google Scholar
• KRUMBHOLZ M, THEIL D, DERFUSS T et al.: BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. I Exp. Med. (2005) 201:195–200.
   PubMed Web of Science ®Google Scholar
• SCAPINI P, CARLETTO A, NARDELLI B et al: Proinflammatory mediators elicit secretion of intracellular B lymphocyte stimulator pool (Blys) that is stored in activated neutrophils: implications for inflammatory diseases. Blood (2005) 105:830–837.
   PubMed Web of Science ®Google Scholar
• OHATA J, ZVAIFFLER N, NISHIO Met al.: Fibroblast-like synoviocytes of mesenchymal origin express functional B cell activating factor of the TNF-family in response to proinflammatory cytokines. Immunol (2005)174:864–870.
   Google Scholar
• RAHMAN ZS, RAO SP, KALLED SL, MANSER T: Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J. Exp. Med. (2003) 198:1157–1169.
   PubMed Web of Science ®Google Scholar
• DO RK, HATADA E, LEE H, TOURIGNY MR, HILBERT D, CHEN-KIANG S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. (2000) 192:953–964.
   PubMed Web of Science ®Google Scholar
• AVERY DT, KALLED SL, ELLYARD JI et al.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. (2003) 14:522–528.
   Google Scholar
• HUARD B, SCHNEIDER P, MAURI D et al.: T cell costimulation by the TNF ligand BAFF. Immunol. (2001) 167:6225–6231.
   Web of Science ®Google Scholar
• SASAKI Y, CASOLA S, KUTOK JL, RAJEWSKY K, SCHMIDT- SUPPRIAN M: TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. (2004) 173:2245–2252.
   PubMed Web of Science ®Google Scholar
• CASTIGLI E, WILSON SA, SCOTT S et al.: TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. (2005) 201:35–39.
   PubMed Web of Science ®Google Scholar
• KALLED SL, AMBROSE C, HSU YM: The biochemistry and biology of BAFF, APRIL and their receptors. Curr. Autoimmun. (2005) 8:206–242.
   PubMedGoogle Scholar
• GROSS JA, DILLON SR, MUDRI S et al: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BlyS. Immunity (2001) 18:289–302.
   Google Scholar
• MARSTERS SA, YAN M, PITTI RM et al.: Interaction of the TNF homologue BLyS and APRIL with the receptor homologues BCMA and TACI. Curr. Biol. (2000) 10:785–788.
   PubMed Web of Science ®Google Scholar
• KHARE SD, HSU H: The role of Tall-1 and APRIL in immune regulation. Trends Immunol. (2001) 22(2):61–63.
   PubMed Web of Science ®Google Scholar
• RENNERT P, SCHNEIDER P, CACHERO TG et al.: A soluble form of B cell maturation antigen, a receptor for tumor necrosis factor family member APRIL inhibits tumour growth. I Exp. Med. (2000) 192:1677–1683.
   PubMed Web of Science ®Google Scholar
• ROSCHKE V, SOSNOVTSEVA S, WARD CD et al: BLyS and APRIL form biologically active heterodimers that are expressed in patients with systemic immune-based rheumatic diseases. Immunol (2002). 169:4314–4321.
   Web of Science ®Google Scholar
• CASTIGLI E, SCOTT S, DEDEOGLU F et al.: Impaired IgA class switching in APRIL-deficient mice. Proc. Natl. Acad. Sci. USA (2004) 101:3903–3908.
   PubMed Web of Science ®Google Scholar
• STOHL W, METYAS S, TAN SM et al:Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. (2004) 63:1096–1103.
   PubMed Web of Science ®Google Scholar
• KOYAMA T, TSUKAMOTO H, MIYAGI Y et al.: Elevated serum APRIL levels in patients with systemic lupus erythematosus. Ann. Rheum. Dis. (2005) 64(7):1065–1067.
   PubMed Web of Science ®Google Scholar
• GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 404:995–999.
   PubMed Web of Science ®Google Scholar
• YAN M, WANG H, CHAN B et al: Activation and accumulation of B cells in TACI deficient mice. Nat. Immunol. (2001) 2:638–643.
   PubMed Web of Science ®Google Scholar
• MACKAY F, WOODCOCK SA, LAWTON P et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. (1999) 190:1697–1710.
   PubMed Web of Science ®Google Scholar
• PARRY TJ, RICCOBENE TA, STRAWN SJ et al: Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. Pharmacol. Exp. Ther. (2001) 296:396–404.
   PubMed Web of Science ®Google Scholar
• GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. (2002) 109:59–68.
   PubMed Web of Science ®Google Scholar
• ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. Immunol (2001) 166:6–10.
   Web of Science ®Google Scholar
• •This paper demonstrates for the first time elevated BAFF serum levels in SLE.
   Google Scholar
• CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. (2001) 44:1313–1319.
   PubMed Web of Science ®Google Scholar
• THIEN M, PHAN TG, GARDAM S et al: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 20:785–798.
   PubMed Web of Science ®Google Scholar
• LESLEY R, XU Y, KALLED SL et al: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 20:441–453.
   PubMed Web of Science ®Google Scholar
• MARIETTE X, ROUX S, ZHANG J et al.: The level of Blys (BAFF) correlates with the titre of autoantibodies in human SjOgren syndrome. Ann. Rheum. Dis. (2003) 62:168–171.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK J, SANZ I: B cells as therapeutic targets for rheumatic diseases Curr. Opin. Rheumatol. (2004) 18:180–185.
   Google Scholar
• LIU W, SZALAI A, ZHAO L et al: Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum. (2004) 50:1884–1896.
   PubMed Web of Science ®Google Scholar
• RAMANUJAM M, WANG X, HUANG W et al.: Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. ./. Immunol. (2004) 173:3524–3534.
   PubMed Web of Science ®Google Scholar
• BAKER KP, EDWARDS BM, MAIN SH et al: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48:3253–3265.
   PubMed Web of Science ®Google Scholar
• O'CONNOR BP, RAMAN VS, ERICKSON LD et al.: BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. (2004) 99:91–97.
   Google Scholar